Exploiting beneficial alloreactive T cells

Vox Sanguinis

Volumn 91, Issue 1, 2006, Pages 20-27

  Barber, L D ^a   Madrigal, J A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Allorecognition; Human leucocyte antigen; T cell; Tolerance; Tumour immunotherapy

Indexed keywords

HLA ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ALLORECOGNITION; ANIMAL CELL; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELL MANIPULATION; CELLULAR IMMUNITY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION;

ADOPTIVE TRANSFER; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOANTIGENS; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 33744774989     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00775.x     Document Type: Review

References (72)

1. Weiden PL Flournoy N Thomas ED Prentice R Fefer A Buckner CD Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979 300: 1068 1073
2. Horowitz MM Gale RP Sondel PM Goldman JM Kersey J Kolb HJ Rimm AA Ringden O Rozman C Speck B: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990 75: 555 562
3. Waldmann H Cobbold S: Exploiting tolerance processes in transplantation. Science 2004 305: 209 212
4. Whitelegg A Barber LD: The structural basis of T-cell allorecognition. Tissue Antigens 2004 63: 101 108
5. Suchin EJ Langmuir PB Palmer E Sayegh MH Wells AD Turka LA: Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001 166: 973 981
6. Matzinger P Bevan MJ: Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977 29: 1 5
7. Whitelegg AM Oosten LE Jordan S Kester M van Halteren AG Madrigal JA Goulmy E Barber LD: Investigation of peptide involvement in T cell allorecognition using recombinant HLA class I multimers. J Immunol 2005 175: 1706 1714
8. Smith PA Brunmark A Jackson MR Potter TA: Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). J Exp Med 1997 185: 1023 1033
9. Baker RJ Hernandez-Fuentes MP Brookes PA Chaudhry AN Cook HT Lechler RI: Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001 167: 7199 7206
10. Simpson E Scott D James E Lombardi G Cwynarski K Dazzi F Millrain M Dyson PJ: Minor H antigens: genes and peptides. Transplant Immunol 2002 10: 115 123
11. Goulmy E Schipper R Pool J Blokland E Falkenburg JH Vossen J Gratwohl A Vogelsang GB van Houwelingen HC van Rood JJ: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996 334: 281 285
12. Mutis T Verdijk R Schrama E Esendam B Brand A Goulmy E: Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999 93: 2336 2341
13. Kolb HJ Schattenberg A Goldman JM Hertenstein B Jacobsen N Arcese W Ljungman P Ferrant A Verdonck L Niederwieser D: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995 86: 2041 2050
14. Childs R Chernoff A Contentin N Bahceci E Schrump D Leitman S Read EJ Tisdale J Dunbar C Linehan WM Young NS Barrett AJ: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000 343: 750 758
15. Collins RH Jr. Shpilberg O Drobyski WR Porter DL Giralt S Champlin R Goodman SA Wolff SN Hu W Verfaillie C List A Dalton W Ognoskie N Chetrit A Antin JH Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997 15: 433 444
16. Fabre JW: The allogeneic response and tumor immunity. Nat Med 2001 7: 649 652
17. Mackinnon S Papadopoulos EB Carabasi MH Reich L Collins NH Boulad F Castro-Malaspina H Childs BH Gillio AP Kernan NA Small TN Young JW O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995 86: 1261 1268
18. Marijt WA Heemskerk MH Kloosterboer FM Goulmy E Kester MG van der Hoorn MA van Luxemburg-Heys SA Hoogeboom M Mutis T Drijfhout JW van Rood JJ Willemze R Falkenburg JH: Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003 100: 2742 2747
19. Fontaine P Roy-Proulx G Knafo L Baron C Roy DC Perreault C: Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001 7: 789 794
20. den Haan JM Sherman NE Blokland E Huczko E Koning F Drijfhout JW Skipper J Shabanowitz J Hunt DF Engelhard VH Goulmy E: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995 268: 1476 1480
21. Stauss HJ: Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999 20: 180 183
22. Sadovnikova E Stauss HJ: Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc Natl Acad Sci USA 1996 93: 13114 13118
23. Gao L Bellantuono I Elsasser A Marley SB Gordon MY Goldman JM Stauss HJ: Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000 95: 2198 2203
24. Bellantuono I Gao L Parry S Marley S Dazzi F Apperley J Goldman JM Stauss HJ: Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002 100: 3835 3837
25. Amrolia PJ Reid SD Gao L Schultheis B Dotti G Brenner MK Melo JV Goldman JM Stauss HJ: Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003 101: 1007 1014
26. Sadovnikova E Jopling LA Soo KS Stauss HJ: Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 1998 28: 193 200
27. Dutoit V Guillaume P Romero P Cerottini JC Valmori D: Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201-donor: exploring tumor antigen allorestricted recognition. Cancer Immunol 2002 2: 7
28. Mutis T Gillespie G Schrama E Falkenburg JH Moss P Goulmy E: Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999 5: 839 842
29. Mommaas B Stegehuis-Kamp JA van Halteren AG Kester M Enczmann J Wernet P Kogler G Mutis T Brand A Goulmy E: Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood 2005 105: 1823 1827
30. Falkenburg JH Wafelman AR Joosten P Smit WM van Bergen CA Bongaerts R Lurvink E van der Hoorn M Kluck P Landegent JE Kluin-Nelemans HC Fibbe WE Willemze R: Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999 94: 1201 1208
31. Moris A Teichgraber V Gauthier L Buhring HJ Rammensee HG: Cutting edge: characterization of allorestricted and peptide-selective alloreactive T cells using HLA-tetramer selection. J Immunol 2001 166: 4818 4821
32. Bonini C Ferrari G Verzeletti S Servida P Zappone E Ruggieri L Ponzoni M Rossini S Mavilio F Traversari C Bordignon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997 276: 1719 1724
33. Oosten LEM Blokland E van Halteren AG Curtsinger J Mescher MF Falkenburg JHF Mutis T Goulmy E: Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood 2004 104: 224 226
34. Savage P Gao L Vento K Cowburn P Man S Steven N Ogg G McMichael A Epenetos A Goulmy E Stauss HJ: Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 2004 103: 4613 4615
35. Stanislawski T Voss RH Lotz C Sadovnikova E Willemsen RA Kuball J Ruppert T Bolhuis RL Melief CJ Huber C Stauss HJ Theobald M: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001 2: 962 970
36. Kessels HW Wolkers MC van den Boom MD van der Valk MA Schumacher TN: Immunotherapy through TCR gene transfer. Nat Immunol 2001 2: 957 961
37. Xue SA Gao L Hart D Gillmore R Qasim W Thrasher A Apperley J Engels B Uckert W Morris E Stauss H: Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005 106: 3062 3067
38. Hacein-Bey-Abina S von Kalle C Schmidt M Le Deist F Wulffraat N McIntyre E Radford I Villeval JL Fraser CC Cavazzana-Calvo M Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003 348: 255 256
39. Wood KJ Sakaguchi S: Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003 3: 199 210
40. Sakaguchi S Sakaguchi N Asano M Itoh M Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995 155: 1151 1164
41. Kingsley CI Karim M Bushell AR Wood KJ: CD25+ CD4+ regulatory T cells prevent graft rejection. CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002 168: 1080 1086
42. Taylor PA Lees CJ Blazar BR: The infusion of ex vivo activated and expanded CD4(+) CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002 99: 3493 3499
43. Cohen JL Trenado A Vasey D Klatzmann D Salomon BL: CD4(+) CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002 196: 401 406
44. Hoffmann P Ermann J Edinger M Fathman CG Strober S: Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002 196: 389 399
45. Levings MK Sangregorio R Roncarolo MG: Human cd25(+) cd4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001 193: 1295 1302
46. Davies JD Leong LY Mellor A Cobbold SP Waldmann H: T cell suppression in transplantation tolerance through linked recognition. J Immunol 1996 156: 3602 3607
47. Cai J Lee J Jankowska-Gan E Derks R Pool J Mutis T Goulmy E Burlingham WJ: Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance. J Exp Med 2004 199: 1017 1023
48. Hara M Kingsley CI Niimi M Read S Turvey SE Bushell AR Morris PJ Powrie F Wood KJ: IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001 166: 3789 3796
49. Yamada A Chandraker A Laufer TM Gerth AJ Sayegh MH Auchincloss H Jr.. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 2001 167: 5522 5526
50. Koksoy S Elpek KG Yolcu ES Shirwan H: Tolerance to rat heart grafts induced by intrathymic immunomodulation is mediated by indirect recognition primed CD4+ CD25+ Treg cells. Transplantation 2005 79: 1492 1497
51. Wells AD Li XC Li Y Walsh MC Zheng XX Wu Z Nunez G Tang A Sayegh M Hancock WW Strom TB Turka LA: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999 5: 1303 1307
52. Baan CC van der Mast BJ Klepper M Mol WM Peeters AM Korevaar SS Balk AH Weimar W: Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005 80: 110 117
53. Kawai M Kitade H Mathieu C Waer M Pirenne J: Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation 2005 79: 1073 1077
54. Coenen JJ Koenen HJ Rijssen EV Hilbrands LB Joosten I: Rapamycin, and not Cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+ CD25+ regulatory T cells. Blood 2006 107: 1018 1023
55. Gregori S Casorati M Amuchastegui S Smiroldo S Davalli AM Adorini L: Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001 167: 1945 1953
56. Andre-Schmutz I Le Deist F Hacein-Bey-Abina S Vitetta E Schindler J Chedeville G Vilmer E Fischer A Cavazzana-Calvo M: Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002 360: 130 137
57. Graca L Thompson S Lin CY Adams E Cobbold SP Waldmann H: Both CD4(+) CD25(+) and CD4(+) CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002 168: 5558 5565
58. Jiang S Camara N Lombardi G Lechler RI: Induction of allopeptide-specific human CD4+ CD25+ regulatory T cells ex vivo. Blood 2003 102: 2180 2186
59. Hoffmann P Eder R Kunz-Schughart LA Andreesen R Edinger M: Large-scale in vitro expansion of polyclonal human CD4(+) CD25 high regulatory T cells. Blood 2004 104: 895 903
60. Jonuleit H Schmitt E Schuler G Knop J Enk AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000 192: 1213 1222
61. Mirenda V Berton I Read J Cook T Smith J Dorling A Lechler RI: Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004 15: 987 997
62. Sakaguchi S Sakaguchi N Shimizu J Yamazaki S Sakihama T Itoh M Kuniyasu Y Nomura T Toda M Takahashi T: Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001 182: 18 32
63. Edinger M Hoffmann P Ermann J Drago K Fathman CG Strober S Negrin RS: CD4+ CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003 9: 1144 1150
64. Riddell SR Watanabe KS Goodrich JM Li CR Agha ME Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992 257: 238 241
65. Finn OJ: Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003 3: 630 641
66. den Haan JM Meadows LM Wang W Pool J Blokland E Bishop TL Reinhardus C Shabanowitz J Offringa R Hunt DF Engelhard VH Goulmy E: The minor histocompatibility antigen HA-1:a diallelic gene with a single amino acid polymorphism. Science 1998 279: 1054 1057
67. Mommaas B Kamp J Drijfhout JW Beekman N Ossendorp F Van Veelen P Den Haan J Goulmy E Mutis T: Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. J Immunol 2002 169: 3131 3136
68. Pierce RA Field ED Mutis T Golovina TN Von Kap-Herr C Wilke M Pool J Shabanowitz J Pettenati MJ Eisenlohr LC Hunt DF Goulmy E Engelhard VH: The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol 2001 167: 3223 3230
69. Spierings E Brickner AG Caldwell JA Zegveld S Tatsis N Blokland E Pool J Pierce RA Mollah S Shabanowitz J Eisenlohr LC van Veelen P Ossendorp F Hunt DF Goulmy E Engelhard VH: The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 2003 102: 621 629
70. Brickner AG Warren EH Caldwell JA Akatsuka Y Golovina TN Zarling AL Shabanowitz J Eisenlohr LC Hunt DF Engelhard VH Riddell SR: The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001 193: 195 206
71. Dolstra H Fredrix H Maas F Coulie PG Brasseur F Mensink E Adema GJ de Witte TM Figdor CG van de Wiel-van Kemenade E: A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999 189: 301 308
72. Akatsuka Y Nishida T Kondo E Miyazaki M Taji H Iida H Tsujimura K Yazaki M Naoe T Morishima Y Kodera Y Kuzushima K Takahashi T: Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med 2003 197: 1489 1500